Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATH-1105 a Phase 1, Double-Blind, Placebo-Controlled, Single-and-Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Male and Female Subjects

Next Previous
X
Search
Trial Profile

ATH-1105 a Phase 1, Double-Blind, Placebo-Controlled, Single-and-Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Male and Female Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATH 1105 (Primary)
  • Indications Amyotrophic lateral sclerosis; Frontotemporal dementia
  • Focus Adverse reactions; First in man
  • Sponsors Athira Pharma

    • Most Recent Events

    • 23 Jan 2025 Status changed from recruiting to completed.
    • 17 Sep 2024 According to an Athira Pharma media release, company expects to complete the full study by year-end 2024, with a goal to begin dosing ALS patients in 2025.
    • 11 Jun 2024 According to an Athira Pharma media release, the company announced it has completed the first cohort of healthy volunteers in its ongoing, first-in-human, dose escalation Phase 1 clinical study evaluating ATH-1105, Completion of this trial is expected by year-end 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top